Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2024 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Total Non-Current Liabilities of $5.3 million for Q1 2026, up 29.08% year-over-year from $4.1 million in Q1 2025, and up 29.08% quarter-over-quarter from $4.1 million in Q1 2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Total Non-Current Liabilities for 3 consecutive years, with $5.3 million the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | 9.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.86 Mn |
| Mar 31, 2026 | 5.31 Mn |
| Mar 31, 2025 | 4.12 Mn |
| Mar 31, 2024 | 4.29 Mn |